| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
FTISADTSK-13C6,15N2 TFA is an isotopically labeled peptide standard. It does not possess inherent biological activity or a therapeutic target. It is used as an analytical internal standard for the detection and quantification of the signature peptide FTISADTSK derived from Trastuzumab, a HER2/neu receptor antagonist. Its utility is for quantitative bioanalysis rather than direct receptor binding.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an impact on a drug's pharmacokinetics and metabolic profile, it has drawn attention [1].
In vitro, FTISADTSK-13C6,15N2 TFA is not studied for independent bioactivity. The compound is used as a stable isotope-labeled internal standard in LC-MS/MS assays to accurately quantify the signature peptide FTISADTSK derived from Trastuzumab in plasma and other biological samples. It allows for precise measurement of Trastuzumab concentrations without altering the peptide's chromatographic properties. |
| ln Vivo |
In vivo studies are not applicable for this stable isotope-labeled internal standard as it is used exclusively for ex vivo bioanalytical purposes. The unlabeled parent peptide FTISADTSK is a signature peptide derived from Trastuzumab, a monoclonal antibody that targets HER2/neu receptor and is used clinically for HER2-positive breast cancer. This labeled standard enables quantitative monitoring of Trastuzumab in patient samples.
|
| Enzyme Assay |
This peptide is designed as an LC-MS/MS internal standard rather than for cell-free biochemical assays. For typical LC-MS/MS use: Prepare calibration standards containing known concentrations of unlabeled FTISADTSK peptide and a fixed concentration of FTISADTSK-13C6,15N2 TFA as internal standard. Separate peptides by reverse-phase liquid chromatography (C18 column). Detect using multiple reaction monitoring (MRM) transitions specific for both labeled and unlabeled peptides. Calculate the unlabeled peptide concentration based on peak area ratio relative to the internal standard.
|
| Cell Assay |
Cell-based assays are not typically performed with this compound as it is an analytical standard. For cell uptake or metabolism studies, treat cells with Trastuzumab (the parent antibody) for 24-72 hours. Harvest cell lysates, digest with trypsin, and add FTISADTSK-13C6,15N2 TFA as internal standard. Quantify the signature peptide by LC-MS/MS to determine Trastuzumab internalization and degradation. Controls should include untreated cells and cells treated with isotype control antibodies.
|
| Animal Protocol |
Animal studies are not performed with this stable isotope-labeled peptide itself. For PK studies of Trastuzumab, administer the antibody to mice or rats via intravenous injection (1-10 mg/kg). Collect plasma at various time points (0-336 hours). Process plasma samples by immunoprecipitation or tryptic digestion, add FTISADTSK-13C6,15N2 TFA as internal standard, and analyze by LC-MS/MS. Quantify Trastuzumab concentrations and calculate PK parameters (Cmax, t1/2, AUC, clearance).
|
| ADME/Pharmacokinetics |
Pharmacokinetics apply only to the unlabeled parent compound Trastuzumab, not the labeled internal standard. Trastuzumab (Herceptin), a monoclonal antibody, has a typical half-life of 5-25 days in humans, with clearance primarily via target-mediated elimination and degradation. The labeled peptide is not administered in vivo. The TFA salt enhances peptide solubility. This compound should be stored at -20degC protected from light.
|
| Toxicity/Toxicokinetics |
This isotopically labeled peptide is considered safe for laboratory use under standard chemical safety guidelines. It is not intended for human consumption or in vivo administration. The TFA salt may cause irritation to eyes, skin, and respiratory tract. Standard laboratory precautions including gloves, lab coat, and safety glasses should be used. No genotoxicity or reproductive toxicity data are available for this labeled peptide.
|
| References |
|
| Additional Infomation |
FTISADTSK-13C6,15N2 TFA is a research-grade stable isotope-labeled peptide exclusively for in vitro bioanalytical applications. It is used as an internal standard for the quantitative determination of Trastuzumab signature peptide by SRM or LC-MS/MS. The compound is derived from Trastuzumab (Herceptin), a humanized monoclonal antibody approved for HER2-positive breast cancer and gastric cancer. The TFA salt enhances solubility.
|
| Molecular Formula |
C3813C6H69F3N815N2O18
|
|---|---|
| Molecular Weight |
1091.01
|
| Related CAS # |
FTISADTSK;1431957-73-1
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~91.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9166 mL | 4.5829 mL | 9.1658 mL | |
| 5 mM | 0.1833 mL | 0.9166 mL | 1.8332 mL | |
| 10 mM | 0.0917 mL | 0.4583 mL | 0.9166 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
